Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoADAPT: Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Stage 2/3 TNBC
NCT06245889Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2024
- Primary completion
- Jun 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06245889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245889.